Can amlodipine cause gum swelling or gingivitis as a side effect?

Amlodipine Can Cause Gum Swelling and Gingivitis

Yes, gum swelling (gingival enlargement/hyperplasia) is a recognized side effect of amlodipine, though it is not listed among the most common adverse effects in the FDA labeling. While the official FDA drug label 1 lists "gingival hyperplasia" under gastrointestinal adverse events occurring in <1% but >0.1% of patients 1, recent clinical research demonstrates this side effect may be substantially more common than previously documented.

Prevalence and Clinical Significance

The actual prevalence of amlodipine-induced gingival enlargement appears significantly higher than FDA labeling suggests:

• Recent studies show 28.7% to 37% prevalence in patients taking amlodipine for at least 3-6 months 2, 3
• Most cases present as Grade 1 enlargement (mild) affecting approximately 18-20% of patients 2, 3
• Severe Grade 3 enlargement is rare, occurring in only 0.9-2% of cases 2, 3

This discrepancy between FDA labeling (<1%) and real-world prevalence (28-37%) likely reflects underreporting in initial clinical trials and increased recognition of this adverse effect over time.

Dose and Duration Relationship

Both dosage and duration of amlodipine therapy correlate significantly with gingival enlargement risk:

• Higher doses (10 mg daily) carry greater risk than lower doses (5 mg) 4, 3
• However, gingival hyperplasia can occur even at 5 mg doses 4, 5
• Minimum exposure time is typically 3-6 months, though cases have been reported after just 2 months at higher doses 4, 3
• The effect occurs whether amlodipine is used alone or in combination with other antihypertensives 3

Clinical Presentation

Patients typically present with:

• Progressive gum swelling and enlargement
• Bleeding from gums during brushing
• Difficulty maintaining oral hygiene
• Aesthetic concerns
• Potential interference with speech and mastication in severe cases 6

Poor oral hygiene and higher plaque index strongly correlate with more severe gingival enlargement 3, suggesting a multifactorial mechanism involving both the drug and local inflammatory factors.

Management Algorithm

First-line treatment: Discontinue amlodipine and substitute with an alternative antihypertensive class 4, 5, 6:

1. Immediate substitution options (per ACC/AHA guidelines 7):

   • ACE inhibitors (e.g., lisinopril 10-40 mg daily)
   • ARBs (e.g., losartan 50-100 mg daily) - specifically shown effective in case reports 5
   • Thiazide diuretics (e.g., chlorthalidone 12.5-25 mg daily)

2. Concurrent oral hygiene measures:

   • Professional dental cleaning
   • Rigorous home oral hygiene
   • Regular dental follow-up

3. Expected outcome: Significant regression of gingival enlargement typically occurs after drug substitution 5, 6

4. Severe cases: May require gingivectomy after drug discontinuation if conservative measures fail

Critical Clinical Pitfalls

Common mistake: Increasing amlodipine dose to 10 mg without warning patients about increased gingival hyperplasia risk, particularly in resource-limited settings where amlodipine is preferred due to low cost 4

Prevention strategy:

• Inform all patients starting amlodipine about this potential side effect before initiation
• Emphasize meticulous oral hygiene from the beginning of therapy 2, 3
• Consider alternative calcium channel blockers or different antihypertensive classes in patients with pre-existing periodontal disease
• Monitor for early signs during follow-up visits

Context from Guidelines

The 2017 ACC/AHA Hypertension Guidelines 7 note that dihydropyridine calcium channel blockers like amlodipine are "associated with dose-related pedal edema" but do not specifically mention gingival hyperplasia in their summary table. This represents a gap between guideline documentation and emerging clinical evidence, though the FDA labeling does acknowledge this adverse effect 1.

Bottom line: While gingival hyperplasia is not among amlodipine's most common side effects like peripheral edema (which affects 5.6-14.6% of patients) 1, it occurs frequently enough (approximately 30% of long-term users) that prescribers should routinely counsel patients about this risk and emphasize preventive oral hygiene measures.